Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 13 September 2017, 13:25 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
The Answer to Viruses and Bacteria in the Home! Eliminates Viruses & Bacteria, Antimicrobial Action that Lasts for 1 Week

TOKYO, Sept 13, 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19 (Tuesday). This product eliminates viruses and bacteria with an antimicrobial action that lasts for one week.

Etak Antimicrobial Spray Alpha

Etak, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component in Etak chemically binds the antimicrobial component to the spray area, providing an antimicrobial effect that lasts for one week.

In the home, there are many surfaces and items, such as doorknobs, bannisters, tables, flooring, and toys, to which viruses and bacteria can spread easily when touched. This product is an answer to the needs of consumers who wish to keep those viruses and bacteria at bay. We suggest habitually using Etak Antimicrobial Spray Alpha to eliminate viruses and bacteria in the home. Additionally, this product contains no alcohol and is both scentless and colorless, making it ideal for use on a wide variety of surfaces and items in the home.

Eisai is also marketing Etak Antimicrobial Spray, an alcohol type spray for mouth masks which uses the same long-acting antimicrobial agent Etak. By spraying it on a mouth mask prior to use, you can prevent viruses and bacteria from collecting on the mask for 24 hours.

Eisai remains committed to ensuring the delivery of products that satisfy the diversified needs of consumers and to making further contributions to increase the benefits provided to them.

Product Outline

1. Product Name: Etak Antimicrobial Spray Alpha (Miscellaneous Goods)

2. Ingredients: Water, long-acting antimicrobial agent (compound containing ethoxysilane), solubilizing agent, stabilizing agent

3. Directions for use:
- Please remove stopper when using. Returning the stopper locks the product.
- Please keep the nozzle 20-30cm away from the target and spray an appropriate amount.
- When using for the first time, please press the spray button a few times to activate the spray mechanism.
- In order to achieve a uniform spread, please wipe the surface with a cloth or other item after spraying.
- Please do not use this product upside down.

4. Volume / Suggested retail price (excluding tax): 250ml / 1,280 yen

5. Manufacturer: Jex Co., Ltd.

6. Supplier: Eisai Co., Ltd.

http://www.acnnewswire.com/topimg/Low_EisaiEtak.jpg
Product Photograph

About long-acting antimicrobial agent Etak

Etak was developed by Professor Hiroki Nikawa of the Department of Oral Health Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented longacting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as adhesive. When a quaternary ammonium salt is sprayed onto an object, it would normally lose its antimicrobial properties upon drying. However, with Etak, the adhesive component chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 2, 2025 16:46 HKT/SGT
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
May 28, 2025 16:45 HKT/SGT
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 21, 2025 14:00 HKT/SGT
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 16, 2025 16:21 HKT/SGT
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
Apr 30, 2025 13:17 HKT/SGT
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 18, 2025 15:52 HKT/SGT
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: